ArticleBMC cancer2025
DHCR24 overexpression is involved in lipid metabolic reprogramming to drive cervical cancer malignant progression and is associated with immune microenvironment.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Transcriptomic landscape reveals segment-specific molecular mechanisms underlying honeycomb-enhanced egg quality in laying hens.Poultry science · 2026Article
- Predictive value of triglyceride combined with age-adjusted D-dimer in patients with early-stage cervical cancer.The Journal of international medical research · 2026Observational
- Article
- Epigenetic and polygenic contributions to body mass index: a validation study of predictive models.Clinical epigenetics · 2026Article
- DHCR24 Drives Ovarian Cancer Chemoresistance Through Lipid Raft-mediated P-gp Stabilization and STAT3 Activation.International journal of biological sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveLipid metabolic reprogramming enables tumor cells to acquire malignant phenotypes, including enhanced proliferative capacity, migratory potential, and invasive properties. In cervical cancer, the precise pathobiological roles and molecular mechanisms of DHCR24 remain unclear.
methodsWe performed comprehensive bioinformatics analyses to investigate the expression patterns, clinical relevance, and prognostic implications of DHCR24 in cervical carcinoma. A prognostic nomogram incorporating tumor stage and DHCR24 expression levels was developed to predict clinical outcomes in patients. Functional studies using SiHa cell lines were conducted to elucidate the oncogenic properties of DHCR24. We used a cholesterol kit to determine the cholesterol content in cervical cancer cells. Finally, we assessed the association between DHCR24 expression and tumor immune microenvironment characteristics through computational analysis of public genomic datasets.
resultsOur analysis revealed significantly elevated DHCR24 expression in cervical carcinoma specimens, demonstrating statistically significant associations with histological subtype, body mass index (BMI), and therapeutic response (P < 0.05). Univariate and Multivariate Cox regression confirmed DHCR24 as an independent prognostic indicator for cervical cancer. The ROC analysis demonstrates that DHCR24 exhibits robust diagnostic performance for cervical cancer detection. Pharmacological inhibition of DHCR24 using U18666A markedly attenuated oncogenic behaviors, suppressing cellular proliferation, migration, and invasion compared to controls (P < 0.05). Notably, intracellular cholesterol levels exhibited a dose-dependent reduction corresponding to the extent of DHCR24 suppression.
conclusionsWe hypothesized that DHCR24 is involved in reprogramming lipid metabolism, especially the cholesterol pathway, to promote tumor progression in cervical cancer and correlates with the tumor-infiltrating immune microenvironment. DHCR24 is a biomarker that predicts the progression and prognosis of cervical cancer and is one of the potential targets for cervical cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.